Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855

NCT01834638 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01834638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01834638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2013
Completion date
November 30, 2014
Enrollment
268 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia